Clinical significance of epithelial–mesenchymal transition typing of circulating tumour cells in colorectal cancer

2020 ◽  
Vol 22 (5) ◽  
pp. 581-587
Author(s):  
J. Hou ◽  
C. Guo ◽  
G. Lyu
Keyword(s):  
Colorectal Cancer ◽  
Clinical Significance ◽  
Epithelial Mesenchymal Transition ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Mesenchymal Transition

Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer

2014 ◽  
Vol 67 (10) ◽  
pp. 848-853 ◽  
Author(s):  
S H-S Lim ◽  
T M Becker ◽  
W Chua ◽  
W L Ng ◽  
P de Souza ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Mesenchymal Transition

scholarly journals Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1879
Author(s):  
Zdeněk Kejík ◽  
Robert Kaplánek ◽  
Petr Dytrych ◽  
Michal Masařík ◽  
Kateřina Veselá ◽  
...  
Keyword(s):  
Anticancer Agents ◽  
Epithelial Mesenchymal Transition ◽  
Small Cell Lung Carcinoma ◽  
Meta Analysis ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Cell Lung Carcinoma ◽  
Mesenchymal Transition ◽  
Standard Methods ◽  
The Impact

Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy of standard treatment methods is insufficient and results in treatment failure and reduced patient survival. CTCs are seen not only as an isolated phenomenon but also a key inherent part of the formation of metastasis and a key factor in cancer death. This review discusses the impact of NSCLC therapy strategies based on a meta-analysis of clinical studies. In addition, possible therapeutic strategies for repression when standard methods fail, such as the administration of low-toxicity natural anticancer agents targeting these phenomena (curcumin and flavonoids), are also discussed. These strategies are presented in the context of key mechanisms of tumour biology with a strong influence on CTC spread and metastasis (mechanisms related to tumour-associated and -infiltrating cells, epithelial–mesenchymal transition, and migration of cancer cells).

scholarly journals Clinical significance of CDX2-positive circulating tumour cells in colorectal cancer patients

2011 ◽  
Vol 104 (6) ◽  
pp. 1000-1006 ◽  
Author(s):  
S C C Wong ◽  
S S M Ng ◽  
M T Cheung ◽  
L Y Luk ◽  
C M L Chan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Clinical Significance ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Colorectal Cancer Patients

scholarly journals Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients

Cancers ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 59 ◽  
Author(s):  
Aleksandra Markiewicz ◽  
Justyna Topa ◽  
Anna Nagel ◽  
Jaroslaw Skokowski ◽  
Barbara Seroczynska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Tumour Cells ◽  
Molecular Heterogeneity ◽  
Stem Cell Markers ◽  
Circulating Tumour Cells ◽  
Breast Cancer Patients ◽  
Mesenchymal Transition

Circulating tumour cells (CTCs) can provide valuable prognostic information in a number of epithelial cancers. However, their detection is hampered due to their molecular heterogeneity, which can be induced by the epithelial-mesenchymal transition (EMT) process. Therefore, current knowledge about CTCs from clinical samples is often limited due to an inability to isolate wide spectrum of CTCs phenotypes. In the current work, we aimed at isolation and molecular characterization of CTCs with different EMT status in order to establish their clinical significance in early breast cancer patients. We have obtained CTCs-enriched blood fraction from 83 breast cancer patients in which we have tested the expression of epithelial, mesenchymal and general breast cancer CTCs markers (MGB1/HER2/CK19/CDH1/CDH2/VIM/PLS3), cancer stem cell markers (CD44, NANOG, ALDH1, OCT-4, CD133) and cluster formation gene (plakoglobin). We have shown that in the CTCs-positive patients, epithelial, epithelial-mesenchymal and mesenchymal CTCs markers were detected at a similar rate (in 28%, 24% and 24%, respectively). Mesenchymal CTCs were characterized by the most aggressive phenotype (significantly higher expression of CXCR4, uPAR, CD44, NANOG, p < 0.05 for all), presence of lymph node metastases (p = 0.043), larger tumour size (p = 0.023) and 7.33 higher risk of death in the multivariate analysis (95% CI 1.06–50.41, p = 0.04). Epithelial-mesenchymal subtype, believed to correspond to highly plastic and aggressive state, did not show significant impact on survival. Gene expression profile of samples with epithelial-mesenchymal CTCs group resembled pure epithelial or pure mesenchymal phenotypes, possibly underlining degree of EMT activation in particular patient’s sample. Molecular profiling of CTCs EMT phenotype provides more detailed and clinically informative results, proving the role of EMT in malignant cancer progression in early breast cancer.

scholarly journals Abstract 1535: Identification of novel epithelial-mesenchymal transition inducers and their clinical significance in colorectal cancer

2020 ◽  
Author(s):  
Satoshi Ishikawa ◽  
Naohiro Nishida ◽  
Shiki Fujino ◽  
Takayuki Ogino ◽  
Hidekazu Takahashi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Clinical Significance ◽  
Epithelial Mesenchymal Transition ◽  
Mesenchymal Transition

Tumour microenvironment: a non-negligible driver for epithelial−mesenchymal transition in colorectal cancer

2021 ◽  
Vol 23 ◽  
Author(s):  
Lei Han ◽  
Shuyi Wang ◽  
Chen Wei ◽  
Yan Fang ◽  
Sihao Huang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Current Knowledge ◽  
Critical Role ◽  
Inflammatory Cells ◽  
Tumour Microenvironment ◽  
Tumour Cells ◽  
Mesenchymal Transition ◽  
Tumour Metastasis ◽  
Favourable Environment

Abstract Cancer remains the leading cause of death worldwide, and metastasis is still the major cause of treatment failure for cancer patients. Epithelial–mesenchymal transition (EMT) has been shown to play a critical role in the metastasis cascade of epithelium-derived carcinoma. Tumour microenvironment (TME) refers to the local tissue environment in which tumour cells produce and live, including not only tumour cells themselves, but also fibroblasts, immune and inflammatory cells, glial cells and other cells around them, as well as intercellular stroma, micro vessels and infiltrated biomolecules from the nearby areas, which has been proved to widely participate in the occurrence and progress of cancer. Emerging and accumulating studies indicate that, on one hand, mesenchymal cells in TME can establish ‘crosstalk’ with tumour cells to regulate their EMT programme; on the other, EMT-tumour cells can create a favourable environment for their own growth via educating stromal cells. Recently, our group has conducted a series of studies on the interaction between tumour-associated macrophages (TAMs) and colorectal cancer (CRC) cells in TME, confirming that the interaction between TAMs and CRC cells mediated by cytokines or exosomes can jointly promote the metastasis of CRC by regulating the EMT process of tumour cells and the M2-type polarisation process of TAMs. Herein, we present an overview to describe the current knowledge about EMT in cancer, summarise the important role of TME in EMT, and provide an update on the mechanisms of TME-induced EMT in CRC, aiming to provide new ideas for understanding and resisting tumour metastasis.

scholarly journals Epithelial-Mesenchymal Transition and MicroRNAs in Colorectal Cancer Chemoresistance to FOLFOX

Pharmaceutics ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 75
Author(s):  
Paula I. Escalante ◽  
Luis A. Quiñones ◽  
Héctor R. Contreras
Keyword(s):  
Colorectal Cancer ◽  
Tumor Cells ◽  
Methylenetetrahydrofolate Reductase ◽  
Epithelial Mesenchymal Transition ◽  
Late Onset ◽  
Dihydropyrimidine Dehydrogenase ◽  
Acquired Resistance ◽  
Potential Effect ◽  
Mesenchymal Transition ◽  
Folfox Chemotherapy

The FOLFOX scheme, based on the association of 5-fluorouracil and oxaliplatin, is the most frequently indicated chemotherapy scheme for patients diagnosed with metastatic colorectal cancer. Nevertheless, development of chemoresistance is one of the major challenges associated with this disease. It has been reported that epithelial-mesenchymal transition (EMT) is implicated in microRNA-driven modulation of tumor cells response to 5-fluorouracil and oxaliplatin. Moreover, from pharmacogenomic research, it is known that overexpression of genes encoding dihydropyrimidine dehydrogenase (DPYD), thymidylate synthase (TYMS), methylenetetrahydrofolate reductase (MTHFR), the DNA repair enzymes ERCC1, ERCC2, and XRCC1, and the phase 2 enzyme GSTP1 impair the response to FOLFOX. It has been observed that EMT is associated with overexpression of DPYD, TYMS, ERCC1, and GSTP1. In this review, we investigated the role of miRNAs as EMT promotors in tumor cells, and its potential effect on the upregulation of DPYD, TYMS, MTHFR, ERCC1, ERCC2, XRCC1, and GSTP1 expression, which would lead to resistance of CRC tumor cells to 5-fluorouracil and oxaliplatin. This constitutes a potential mechanism of epigenetic regulation involved in late-onset of acquired resistance in mCRC patients under FOLFOX chemotherapy. Expression of these biomarker microRNAs could serve as tools for personalized medicine, and as potential therapeutic targets in the future.

Sign in / Sign up

Export Citation Format

Share Document